Synoligo about us

About Us

Headquartered in Morrisville, NC, USA, Synoligo Biotechnologies is a Contract Research and Development Organization (CRDO) specialized in manufacturing complex and highly modified oligonucleotide for academic, biotech start-up and large pharmaceutical communities. Synoligo is a leading oligonucleotide manufacturing company providing high quality, cost-effective custom oligonucleotides at varying scales for research, diagnostic, and therapeutic applications.

Our Facility

Our Team

Our Team

At the core of our values is the unwavering commitment to providing the highest quality of products and empowering our clients to excel in their primary focus, scientific discoveries. Our founders have curated a stellar team comprising experts in synthetic chemistry, instrumentation, chromatography, and commercialization. With decades of combined experience, each team member is passionately dedicated to the pursuit of our common goal.

Our Facility

Synoligo’s facility is strategically positioned at the heart of the Research Triangle Park, where there’s an unparalleled access to a talent pool from renowned U.S. universities, 5 minutes from RDU international airport, and strong connection to the biotech network within the area

Leadership Team

Founder & CEO

Dr. Xibo Li

Dr. Xibo Li Linkedin Profile

A trained organic chemist with a specialization in nucleic acid chemistry, Xibo began his journey at the University of Utah. His career took a significant turn in 2015 when he joined Nitto Avecia, spearheading the process development for oligonucleotide therapeutic GMP manufacturing. In 2018, he transitioned to LGC Biosearch, where he played a pivotal role in establishing a groundbreaking Nucleic Acid Therapeutic CDMO business at the Petaluma site. Over the subsequent four years, under his leadership, the business unit achieved an impressive 83% Compound Annual Growth Rate (CAGR). As a distinguished member of the LGC group Leadership Team, he not only fulfilled his regular responsibilities in the NAT (Axolabs) business unit but also played an integral role in the technical and advisory aspects of LGC's controlled pore glass, research and diagnostic oligo production portfolios in California operation and the Mermade synthesizer portfolio. Beyond his corporate role, he has been a sought-after consultant for numerous startup companies, providing invaluable insights into their CMC needs.​

Co-Founder & CTO

Dr. Baozhong Zhao

Dr. Baozhong Zhao Linkedin Profile

A seasoned organic chemist with 17+ years in oligonucleotide chemistry and biological research. With a six-year stint at Bio-Synthesis Inc., leading R&D for therapeutic and diagnostic oligo production, Baozhong joined LGC Biosearch in 2020 as Principal Scientist. In 2021, he took the helm at Janssen Pharmaceutical Companies of Johnson & Johnson, earning the 2021 Janssen R&D VP Award and SPARK Award. He spearheaded the establishment of in-house capacity for high-throughput and scaled-up oligo synthesis, managing external partnerships for project deliverables. His success extends to supporting technology transfer for oligo synthesis within portfolio projects from discovery to CMC teams.

Core Values that Guide Our Decisions and Actions


We uphold the highest ethical standards in all aspects of our work, from the quality of our products to the way we treat our team members.​


We believe in building and maintaining trust with our clients, employees and partner through open communication, being transparent in our actions and consistently delivering on our promises.​


We are committed to deliver the best possible services and products for the communities we serve. Our pursuit of excellence is driven by our commitment. ​


We encourage idea sharing and teamwork because we want to harness the power of innovation from the collective expertise of diverse minds.​